Key Points
- CEO Daniel Barber sold 25,000 AQST shares for approximately $105,500, reducing his direct ownership by 3.83%. The transaction was made under a pre-arranged Rule 10b5-1 plan.
- AQST shares fell to $3.78, while the company reported a quarterly loss of $0.18 per share—worse than analysts’ expected $0.10 loss—despite revenue of $13.82 million exceeding estimates.
- The FDA accepted Aquestive’s resubmitted application for Anaphylm, an investigational treatment for severe allergic reactions, with a decision expected March 16, 2027. Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an $8.60 price target.
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the transaction, the chief executive officer directly owned 627,317 shares in the company, valued at approximately $2,647,277.74. This trade represents a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Barber also recently made the following trade(s):
- On Tuesday, September 15th, Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $4.82, for a total transaction of $120,500.00.
Aquestive Therapeutics Stock Performance
Shares of NASDAQ:AQST traded down $0.28 during mid-day trading on Friday, hitting $3.78. The stock had a trading volume of 5,245,984 shares, compared to its average volume of 2,138,648. The company has a market cap of $474.43 million, a PE ratio of -5.82 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 12-month low of $2.93 and a 12-month high of $7.55. The company's 50 day moving average is $4.74 and its 200-day moving average is $4.35.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analysts' expectations of $11.42 million. On average, equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.50 EPS for the current fiscal year.
Institutional Trading of Aquestive Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Sugar Maple Asset Management LLC boosted its holdings in shares of Aquestive Therapeutics by 5.9% during the first quarter. Sugar Maple Asset Management LLC now owns 58,060 shares of the company's stock worth $241,000 after purchasing an additional 3,210 shares during the period. International Assets Investment Management LLC increased its stake in Aquestive Therapeutics by 27.0% in the 1st quarter. International Assets Investment Management LLC now owns 22,895 shares of the company's stock valued at $95,000 after buying an additional 4,870 shares during the period. Quantinno Capital Management LP increased its stake in Aquestive Therapeutics by 52.8% in the 1st quarter. Quantinno Capital Management LP now owns 18,014 shares of the company's stock valued at $75,000 after buying an additional 6,221 shares during the period. Engineers Gate Manager LP increased its stake in Aquestive Therapeutics by 20.5% in the 2nd quarter. Engineers Gate Manager LP now owns 49,879 shares of the company's stock valued at $207,000 after buying an additional 8,496 shares during the period. Finally, Corsair Capital Management L.P. lifted its position in Aquestive Therapeutics by 16.7% in the 1st quarter. Corsair Capital Management L.P. now owns 70,000 shares of the company's stock worth $290,000 after buying an additional 10,000 shares in the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.
Aquestive Therapeutics News Roundup
Here are the key news stories impacting Aquestive Therapeutics this week:
- Positive Sentiment: The FDA accepted Aquestive’s resubmitted New Drug Application for Anaphylm, its investigational sublingual film for severe allergic reactions and anaphylaxis. The filing was deemed complete, with a PDUFA action date of March 16, 2027. If approved, Anaphylm could become the first oral rescue treatment for anaphylaxis, significantly expanding AQST’s commercial opportunity. Aquestive Therapeutics Announces FDA Acceptance of Anaphylm NDA Resubmission
- Positive Sentiment: The resubmission reportedly includes improved human-factors data showing a substantial reduction in packaging and administration errors, addressing previous FDA concerns. One analyst upgraded AQST to Buy and projected potential Anaphylm revenue exceeding $250 million annually by 2030, although competition and reimbursement remain risks. Aquestive FDA Acceptance of Anaphylm Resubmission Makes for Rating Upgrade
- Neutral Sentiment: AQST CEO Daniel Barber sold 25,000 shares for approximately $105,500, reducing his direct position by 3.83%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which lessens its significance as a discretionary bearish signal. SEC Insider Transaction Filing
- Negative Sentiment: Options trading was unusually defensive, with investors purchasing 11,658 put options—about 390% above typical volume—suggesting increased hedging or bearish speculation around AQST.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on AQST shares. Cantor Fitzgerald restated an "overweight" rating and issued a $11.00 target price on shares of Aquestive Therapeutics in a report on Thursday, September 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Thursday. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday. Finally, Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 12th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.60.
Read Our Latest Stock Analysis on AQST
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics, Inc is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company's oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.
Aquestive's commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
